Colibactin

2 papers4 findings

PubChem 138805674 ChEBI 156303 MeSH C569566

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Centre Hospitalier Universitaire de Clermont-Ferrand and 3 more

Animals1

Outcomes

Cellular senescence

upin mice1

1 study

Colibactin induces cellular senescence in mice.
“Growth was sustained by cellular senescence (a direct consequence of small ubiquitin-like modifier (SUMO)-conjugated p53 accumulation), which was accompanied by the production of hepatocyte growth factor (HGF).”
Animalsinfection with colibactin-producing E. coli
Bacterial genotoxin colibactin promotes colon tumour growth by inducing a senescence-associated secretory phenotype
Gut21 Mar 2014

Associations

Early-onset colorectal cancer

upin humans1

1 study

Colibactin is associated with early-onset colorectal cancer in humans.
“Particularly important are emerging genomic data linking colibactin-associated mutational signatures to younger-onset disease, supporting the hypothesis that microbial genotoxicity may imprint early driver events long before clinical diagnosis.”
Review
Early-Onset Colorectal Cancer: From Epidemiologic Shift to Life-Course Carcinogenesis and Age-Attuned Care
Current oncology reports20 Aug 2026